- Johnson & Johnson (NYSE:JNJ) has reportedly ended its negotiations with Actelion Pharmaceuticals (OTCPK:ALIOF) about a possible merger. J&J had made a $20B ($250/share) for the Basel, Switzerland-based biopharma firm, up from its original offer of $17B after Actelion resisted.
- Sanofi (SNY) is reportedly mulling a bid as well.
- Update: In a statement, J&J says its was unable to reach an agreement that it believed would "create adequate value" for its shareholders.
Johnson & Johnson backs away from Actelion
Recommended For You
About JNJ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
JNJ | - | - |
Johnson & Johnson |